Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,219
datasets available to search
ShareScore release 0.9.0
Dataset results
1,219 results for “randomisation”
Effects of a Second-generation Mindfulness-based Intervention on Quality of Life, Pain Management, and Psycho-spiritual Wellbeing in Cancer Patients: A Randomised Controlled Trial
ClinicalTrials.gov study NCT06695234. IPD Sharing: YES. Countries: 1. Publications: 8.
A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Pers
ClinicalTrials.gov study NCT01152450. IPD Sharing: Not stated. Countries: 5. Publications: 1.
A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
ClinicalTrials.gov study NCT00880048. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Rethinking Pulmonary Rehabilitation - a Three-arm Randomised Multicentre Trial
ClinicalTrials.gov study NCT05664945. IPD Sharing: NO. Countries: 1. Publications: 1.
This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream
ClinicalTrials.gov study NCT03802344. IPD Sharing: Not stated. Countries: 2. Publications: 3.
Home-based exercise for people living with frailty and chronic kidney disease: a mixed-methods pilot randomised controlled trial
Open the record for dataset details and reuse information.
Protocol, case report(s), ethics approvals, informed consent, inclusion and exclusion criteria underlying: The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial
Open the record for dataset details and reuse information.
Data from: Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial
Open the record for dataset details and reuse information.
Effectiveness of screening and ultra-brief intervention for hazardous drinking in primary care: pragmatic cluster randomised controlled trial
Open the record for dataset details and reuse information.
Pharmacokinetics parameters, bioanalytical method underlying the manuscript: The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover non-randomised trial
Open the record for dataset details and reuse information.
Data from: Effect of information about the benefits and harms of mammography on women's decision making: the InforMa randomised controlled trial
Open the record for dataset details and reuse information.
The impact of weekly fever-screening and treatment and monthly RDT testing and treatment on the infectious reservoir of malaria in Burkina Faso: results from a cluster-randomised trial
Open the record for dataset details and reuse information.
Randomised trials in maternal and perinatal health in low- and middle-income countries from 2010 to 2019: A systematic scoping review
Open the record for dataset details and reuse information.
Pharmacodynamics parameters underlying the manuscript: The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial
Open the record for dataset details and reuse information.
Extended data for behavioural change for Parkinson’s disease: A randomised controlled feasibility study to promote physical activity and exercise adherence among people with Parkinson’s, study protocol
Open the record for dataset details and reuse information.
Oral ivermectin versus 5% permethrin cream to treat children and adults with classic scabies: multicenter, assessor-blinded, cluster-randomised clinical trial
Open the record for dataset details and reuse information.
Data and statistical codes for: Reliability of urological telesurgery compared to local surgery: A multicenter, randomised controlled trial
Open the record for dataset details and reuse information.
Dataset from "Is It Useful To Treat Blastocystis spp? A double-blind placebo-controlled randomised trial"
<p>Dataset as STATA (.dta) files with corresponding do-files used for statistical analysis and tables.<br> Study registered on clinicaltrials.gov under the NTC number : 01521403</p>
Data from: Sleep, major depressive disorder and Alzheimer's disease: a Mendelian randomisation study
<div class="WordSection1"> <span><span>Objective</span></span> <p><span>To explore the causal relationships between sleep, major depressive disorder (MDD), and Alzheimer's disease (AD).</span></p> <span><span>Methods</span></span> <p><span>We conducted bi-directional two-sample Mendelian randomisation analyses. Genetic associations were obtained from the largest genome-wide association studies currently available in UK Biobank (N=446,118), the Psychiatric Genomics Consortium (N=18,759), and the International Genomics of Alzheimer's Project (N=63,926). We used the inverse variance weighted Mendelian randomisation method to estimate the causal effects, and the weighted median and MR-Egger for sensitivity analyses to test for pleiotropic effects. </span></p> <span><span>Results</span></span> <p><span>We found that higher risk of AD was significantly associated with being a "morning person" (odds ratio (OR)=1.01, P=0.001), shorter sleep duration (self-reported: β=-0.006, P=1.9×10<sup>-4</sup>; accelerometer-based: β=-0.015, P=6.9×10<sup>-5</sup>), less likely to report long sleep (β=-0.003, P=7.3×10<sup>-7</sup>), earlier timing of the least active 5 hours (β=-0.024, P=1.7×10<sup>-13</sup>), and a smaller number of sleep episodes (β=-0.025, P=5.7×10<sup>-14</sup>) after adjusting for multiple comparisons. We also found that higher risk of AD was associated with lower risk of insomnia (OR=0.99, P=7×10<sup>-13</sup>). However, we did not find evidence that these abnormal sleep patterns were causally related to AD or a significant causal relationship between MDD and risk of AD. </span></p> <span><span>Conclusion</span></span> <p><span>We found that AD may causally influence sleep patterns. However, we did not find evidence supporting a causal role of disturbed sleep patterns in AD or evidence for a causal relationship between MDD and AD risk.</span></p> </div> <p> </p>
Data from: Cost-effectiveness of a specialist geriatric medical intervention for frail older people discharged from acute medical units: economic evaluation in a two-centre randomised controlled trial (AMIGOS)
Background: Poor outcomes and high resource-use are observed for frail older people discharged from acute medical units. A specialist geriatric medical intervention, to facilitate Comprehensive Geriatric Assessment, was developed to reduce the incidence of adverse outcomes and associated high resource-use in this group in the post-discharge period. Objective: To examine the costs and cost-effectiveness of a specialist geriatric medical intervention for frail older people in the 90 days following discharge from an acute medical unit, compared with standard care. Methods: Economic evaluation was conducted alongside a two-centre randomised controlled trial (AMIGOS). 433 patients (aged 70 or over) at risk of future health problems, discharged from acute medical units within 72 hours of attending hospital, were recruited in two general hospitals in Nottingham and Leicester, UK. Participants were randomised to the intervention, comprising geriatrician assessment in acute units and further specialist management, or to control where patients received no additional intervention over and above standard care. Primary outcome was incremental cost per quality adjusted life year (QALY) gained. Results: We undertook cost-effectiveness analysis for 417 patients (intervention: 205). The difference in mean adjusted QALYs gained between groups at 3 months was -0.001 (95% confidence interval [CI]: -0.009, 0.007). Total adjusted secondary and social care costs, including direct costs of the intervention, at 3 months were £4412 (€5624, $6878) and £4110 (€5239, $6408) for the intervention and standard care groups, the incremental cost was £302 (95% CI: 193, 410) [€385, $471]. The intervention was dominated by standard care with probability of 62%, and with 0% probability of cost-effectiveness (at £20,000/QALY threshold). Conclusions: The specialist geriatric medical intervention for frail older people discharged from acute medical unit was not cost-effective. Further research on designing effective and cost-effective specialist service for frail older people discharged from acute medical units is needed.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.